Pharmacology of apolipoprotein A-l
- 1 August 1997
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 8 (4) , 225-228
- https://doi.org/10.1097/00041433-199708000-00006
Abstract
The role of HDL and its main protein component the apolipoprotein A-l as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms. Depending upon the stage and type of atherosclerosis, different mechanisms may be more or less important. Knowledge of pharmacology of apolipoprotein A-l has strongly increased during past years and clinical studies have started with infusions of apolipoprotein A-l phospholipid complexes.Keywords
This publication has 0 references indexed in Scilit: